{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:28:21Z","timestamp":1774686501093,"version":"3.50.1"},"reference-count":25,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiology"],"published-print":{"date-parts":[[2011]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; Prescription omega-3-acid ethyl esters (PO-3A) have been tested for outcome benefits in patients with coronary artery disease (CAD), arrhythmias and heart failure. Some evidence suggests that PO-3A may exert their benefit via inhibiting platelets. We tested the hypothesis that PO-3A may inhibit platelet activity in patients with documented stable CAD, beyond the antiplatelet properties of aspirin and statins. &lt;i&gt;Methods:&lt;\/i&gt; Thirty patients with documented CAD and triglycerides over 250 mg\/dl treated with aspirin (70\u2013160 mg\/daily) and statins (simvastatin equivalence dose: 5\u201340 mg\/daily) were randomized 1:1:1 to Omacor\u2122 1 g\/day (DHA\/EPA ratio 1.25:1.0), Omacor 2 g\/day, or a placebo for 2 weeks. Platelet tests including aggregometry and flow cytometry and cartridge analyzer readings were performed at baseline and at 1 and 2 weeks following PO-3A therapy. &lt;i&gt;Results:&lt;\/i&gt; ADP-induced platelet aggregation (p = 0.037), GP IIb\/IIIa antigen (p = 0.031) and activity (p = 0.024), and P-selectin (p = 0.041) were significantly reduced after PO-3A, while platelet\/endothelial cell adhesion molecule (p = 0.09), vitronectin receptor (p = 0.16), formation of platelet-monocyte microparticles (p = 0.19) and the VerifyNow IIb\/IIIa test (p = 0.27) only exhibited nonsignificant trends suggestive of reduced platelet activity. Finally, collagen- and arachidonic acid-induced aggregation, closure time with the PFA-100 device and expression of thrombospondin (CD36), GP Ib (CD42b), LAMP-3 (CD63), LAMP-1 (CD107a), CD40-ligand (CD154), GP37 (CD165), and PAR-1 receptor intact (SPAN 12) and cleaved (WEDE-15) epitopes were not affected by 2 weeks of PO-3A. &lt;i&gt;Conclusion:&lt;\/i&gt; Independently of the dose and already at 1 week, short-term therapy with PO-3A provided a modest reduction of platelet activity biomarkers, despite concomitant aspirin and statin therapy, when compared to a placebo. The effect of PO-3A is unique, differs from other known antiplatelet agents and suggests potential pleiotropism. These preliminary randomized data call for confirmation in prospective studies.<\/jats:p>","DOI":"10.1159\/000329300","type":"journal-article","created":{"date-parts":[[2011,6,22]],"date-time":"2011-06-22T13:57:55Z","timestamp":1308751075000},"page":"187-194","source":"Crossref","is-referenced-by-count":25,"title":["Early Impact of Prescription Omega-3 Fatty Acids on Platelet Biomarkers in Patients with Coronary Artery Disease and Hypertriglyceridemia"],"prefix":"10.1159","volume":"118","author":[{"given":"Victor L.","family":"Serebruany","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex N.","family":"Pokov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesper K.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Hall\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Atar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2011,6,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161%2F01.CIR.0000059746.10326.09"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.jacc.2010.11.017"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161%2F01.CIR.0000038493.65177.94"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.plefa.2006.07.009"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007%2Fs00228-004-0758-8"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016%2FS0049-3848%2800%2900313-3"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007%2Fs11010-005-2324-9"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1055%2Fs-2007-995840"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1749-6632.1993.tb38785.x"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161%2F01.CIR.0000014682.14181.F2"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001%2Fjama.287.14.1815"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007%2Fs11883-008-0078-z"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.clinthera.2007.07.018"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.ahj.2010.10.032"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016%2FS0049-3848%2803%2900284-6"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001%2Fjama.292.12.1440"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1440-1681.2002.03746.x"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.ahj.2005.03.001"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1524-6175.2005.04809.x"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.amjcard.2005.11.058"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1160%2FTH10-01-0015"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007%2FBF02333013"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.amjcard.2006.11.021"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.jacc.2009.11.080"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.plefa.2010.11.004"}],"container-title":["Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/329300","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/329300","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/329300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:18:17Z","timestamp":1745432297000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000329300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2011,7,1]]},"published-print":{"date-parts":[[2011,7,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000329300","archive":["Portico"],"relation":{},"ISSN":["0008-6312","1421-9751"],"issn-type":[{"value":"0008-6312","type":"print"},{"value":"1421-9751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}